A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
← catalyst calendarNCT07175285 · readout in 583 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
223estimated
Sites
65
Countries
Argentina, Brazil, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-08 | actual | When the study began enrolling |
| Primary completion | 2028-03-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-10-05 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus (SLE)
Intervention
- Drug: Current standard of care treatment options
Primary outcome
what the primary-completion date above is the date OFNumber of of participants achieving Definition of Remission in Systemic Lupus Erythematosus (DORIS) at 6 months along with the 95% CI.
measured 6 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed